文献速递泌尿生殖与妇科肿瘤放疗

局限性前列腺癌男性放疗未完成的影响因素

Factors Influencing Noncompletion of Radiation Therapy Among Men With Localized Prostate Cancer.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2020-12-01

基于美国国家癌症数据库2004至2014年157657例接受根治性放疗的局限性前列腺癌男性,分析放疗未完成率与分割方案的关系。常规分割未完成率为12.5%,SBRT为1.9%(OR 0.21,95%CI 0.18-0.26,P<.001)。非裔美国患者未完成率高于白人(12.8% vs 11.8%,OR 1.14,P<.001),该差异在常规分割中持续存在,但在SBRT中未观察到。未完成放疗与更差的总生存相关(HR 1.25,95%CI 1.22-1.29,P<.001)。

要点

  • SBRT与常规分割相比,放疗未完成率显著更低(1.9% vs 12.5%)。
  • 非裔美国患者放疗未完成率高于白人,但SBRT可能缩小该差异。
  • 放疗未完成与更差的总生存独立相关(HR 1.25)。

核心结论

  • 在局限性前列腺癌男性中,SBRT与较低的放疗未完成率相关。
  • 非裔美国种族与较高的放疗未完成率相关,但该差异在SBRT中可能减小。
  • 放疗未完成与更差的总生存相关。

研究设计与样本

  • 回顾性队列研究,使用美国国家癌症数据库2004至2014年诊断为局限性前列腺癌并接受根治性放疗的男性157657例。
  • 常规分割定义为180 cGy/次或200 cGy/次,完成放疗分别需≥41次或≥37次;SBRT定义为5至8次、600至800 cGy/次。
  • 采用校正社会人口学协变量的比值比比较未完成率,并用倾向性校正多变量Cox回归评估完成与总生存的关系。

主要发现

  • 157657例中95.7%(150847例)接受常规分割,4.3%(6810例)接受SBRT。
  • 常规分割未完成率为12.5%(18803例),SBRT为1.9%(131例),SBRT相对常规分割的OR为0.21(95%CI 0.18-0.26,P<.001)。
  • 25727例非裔美国患者未完成率为12.8%,126199例白人患者为11.8%(OR 1.14,95%CI 1.09-1.19,P<.001)。
  • 亚组分析中,常规分割未完成率非裔美国患者13.2% vs 白人12.3%(OR 1.09,95%CI 1.05-1.13,P<.001);SBRT为2.2% vs 1.8%(OR 1.26,95%CI 0.79-2.00,P=.34)。
  • 倾向性校正多变量分析显示未完成放疗与更差生存相关(HR 1.25,95%CI 1.22-1.29,P<.001)。

关键数值与推荐

  • 常规分割完成标准:180 cGy/次需≥41次,或200 cGy/次需≥37次。
  • SBRT定义:5至8次,每次600至800 cGy。
  • SBRT vs 常规分割未完成OR 0.21(95%CI 0.18-0.26,P<.001)。
  • 非裔美国 vs 白人未完成OR 1.14(95%CI 1.09-1.19,P<.001)。
  • 未完成放疗与总生存的HR 1.25(95%CI 1.22-1.29,P<.001)。

临床怎么用

  • 对于局限性前列腺癌男性,选择SBRT可能降低放疗未完成的风险。
  • 对非裔美国患者等未完成高危人群,应加强治疗依从性支持。
  • 放疗未完成与更差生存相关,临床应监测并干预治疗中断。

局限性

  • 回顾性数据库研究,可能存在未测量混杂。
  • 未完成定义基于分割次数阈值,可能受方案变异影响。
  • SBRT组样本量较小(6810例),亚组分析效能有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Treatment noncompletion may occur with radiation therapy (RT), especially with protracted treatment courses such as RT for prostate cancer, and may affect the efficacy of RT. For men with localized prostate cancer managed with primary RT, we evaluated associations between rates of treatment noncompletion and RT fractionation schedules. METHODS AND MATERIALS: The National Cancer Database identified men diagnosed from 2004 to 2014 treated with primary RT. Patients receiving 180 cGy/fraction or 200 cGy/fraction were defined as having completed radiation therapy if they received ≥41 fractions of 180 cGy/fraction or ≥37 fractions of 200 cGy/fraction. Stereotactic body radiation therapy (SBRT) was defined as 5 to 8 fractions of 600 to 800 cGy/fraction. Odds ratios compared rates of treatment noncompletion, adjusting for sociodemographic covariates. A propensity-adjusted multivariable Cox regression assessed the association between treatment completion and overall survival. RESULTS: Of 157,657 patients, 95.7% (n = 150,847) received conventional fractionation and 4.3% (n = 6810) received SBRT. Rates of noncompletion were 12.5% (n = 18,803) among patients who received conventional fractionation and 1.9% (n = 131) among patients who received SBRT (odds ratio [OR] versus conventional, 0.21; 95% confidence interval [CI], 0.18-0.26; P < .001). The rate of noncompletion among 25,727 African American patients was 12.8%, compared with 11.8% among 126,199 white patients (OR, 1.14; 95% CI, 1.09-1.19; P < .001). In a subgroup analysis, the disparity in noncompletion persisted for conventional fractionation (13.2% vs 12.3%, respectively; OR, 1.09; 95% CI, 1.05-1.13; P < .001), but not for SBRT (2.2% vs 1.8%, respectively; OR, 1.26; 95% CI, 0.79-2.00; P = .34). Noncompletion was associated with worse survival in a propensity-adjusted multivariable analysis (hazard ratio, 1.25; 95% CI, 1.22-1.29; P < .001). CONCLUSIONS: SBRT was associated with lower rates of RT noncompletion among men with localized prostate cancer. African American race was associated with greater rates of treatment noncompletion, although the disparity may be decreased among men receiving SBRT.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Dee EC, Muralidhar V, Arega MA, et al. Factors Influencing Noncompletion of Radiation Therapy Among Men With Localized Prostate Cancer. Int J Radiat Oncol Biol Phys. 2020. PMID: 33276019. doi:10.1016/j.ijrobp.2020.11.064

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。